A 48-year-old woman with severe aortic regurgitation (AR) secondary to endocarditis presents with acute dyspnoea and pulmonary oedema. She is haemodynamically unstable with a blood pressure of 90/50 mmHg. Which drug is contraindicated in her acute management?

Explanation

## Acute Severe AR with Haemodynamic Compromise **Key Point:** In acute severe aortic regurgitation with hypotension and pulmonary oedema, beta-blockers are contraindicated because they increase diastolic filling time, which worsens the regurgitant volume and increases left ventricular end-diastolic pressure (LVEDP), exacerbating pulmonary congestion. ### Pathophysiology of Acute AR **High-Yield:** The haemodynamic problem in acute severe AR: - Sudden regurgitant jet into the left ventricle during diastole - LV is unprepared (no time for eccentric hypertrophy) - Rapid rise in LVEDP → pulmonary oedema - Reduced aortic diastolic pressure → reduced coronary perfusion - Tachycardia is a **compensatory mechanism** — it shortens diastole and reduces regurgitant volume **Warning:** Beta-blockers slow heart rate and **lengthen diastole**, allowing more blood to regurgitate back into the LV. This is the opposite of what you want in acute AR. ### Pharmacotherapy in Acute Severe AR | Agent | Mechanism | Effect on Diastole | Use in Acute AR | Notes | |-------|---|---|---|---| | **Nitroprusside** | Arterial + venous dilator | Reduces afterload | ✓ First-line | Decreases regurgitant volume | | **Dobutamine** | β1 agonist + vasodilator | Increases HR, ↓ diastole | ✓ Adjunct | Inotropic support + afterload reduction | | **Hydralazine** | Arterial dilator | Reduces afterload | ✓ Alternative | Decreases regurgitant volume | | **Metoprolol** | β-blocker | Lengthens diastole | ✗ Contraindicated | Worsens regurgitation | **Clinical Pearl:** The goal in acute AR is **rapid afterload reduction** (to decrease regurgitant volume) and **maintaining tachycardia** (to shorten diastole). Nitroprusside is ideal because it is a potent, rapid-acting vasodilator that achieves both. Dobutamine provides additional inotropic support in the setting of hypotension. ### Why Each Agent Works or Fails 1. **Nitroprusside:** Reduces systemic vascular resistance (SVR) → decreases the driving pressure for regurgitation → reduces regurgitant volume and LVEDP. Rapid onset and titratability make it ideal for acute management. 2. **Dobutamine:** β1-mediated inotropy increases contractility and heart rate (shortens diastole), while its vasodilatory effects reduce afterload. Useful for haemodynamic support. 3. **Hydralazine:** Pure arterial dilator; reduces afterload and regurgitant volume. Slower onset than nitroprusside but acceptable alternative. 4. **Metoprolol (CONTRAINDICATED):** Lengthens diastole → increases regurgitant volume → worsens pulmonary oedema and haemodynamic collapse. ### Definitive Management **Key Point:** Acute severe AR from endocarditis requires **urgent surgical valve replacement**. Medical management (vasodilators, diuretics) is a temporizing bridge to surgery, not definitive therapy. Delay in surgical consultation is a common pitfall. ### Mnemonic: "AVOID" in Acute AR - **A**ngiotensin inhibitors (can cause excessive hypotension) - **V**asodilators (nitroprusside, hydralazine) — **GOOD** (confusing mnemonic, but remember: use vasodilators) - **O**pioids (reduce sympathetic drive) - **I**notropes negative (beta-blockers) — **BAD** - **D**iuretics (cautiously, to reduce pulmonary oedema)